TACSTD2 and stomatitis: For example, Dato-DXd targeting TROP2 has an attenuated drug-to-antibody ratio of 4, while other DXd-containing ADCs (e.g., T-DXd, HER3-DXd, and CDH6-DXd) have drug-to-antibody ratios of 7-8, likely due to drug-related adverse events that are consistent with TROP2 expression in normal tissues (e.g., rash, stomatitis, and mucositis) [1].